Bioceres Crop Solutions (BIOX) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Company overview and business model
Develops and commercializes productivity solutions for regenerative agriculture and climate-resilient crops, leveraging a proprietary biotech platform with patented technologies for seeds, microbial ag-inputs, and crop nutrition and protection products.
Product portfolio includes biological crop nutrition, biocontrol products, next-generation fertilizers, and seed traits, marketed in over 45 countries, with a strong presence in South America, the US, and Europe.
Holds or licenses over 1,600 brands, 579 registered products, and more than 750 patents and applications as of June 30, 2024.
Risk factors and disclosures
Risks include those detailed in the most recent annual report, such as market, regulatory, operational, and geopolitical risks, which could adversely affect business, financial condition, and share price.
Forward-looking statements are subject to uncertainties, including market trends, regulatory approvals, integration of acquisitions, and global events.
Market opportunity and competitive landscape
Positioned as a flagship provider and natural partner for global conglomerates in agricultural solutions, with a unique biotech platform and leading infrastructure.
Focuses on expanding to new markets, diversifying product portfolio, and forming strategic partnerships.
Latest events from Bioceres Crop Solutions
- FY24 revenue up 11% to $464.8M, with U.S. HB4 approval boosting future growth.BIOX
Q4 20249 Jul 2026 - Revenue fell 28% but cash flow surged, with Rinotec approval and restructuring driving future growth.BIOX
Q3 20259 Jul 2026 - Gross margin steady at 40% amid sector headwinds; $179M Pro Farm impairment after foreclosure.BIOX
Q2 202629 May 2026 - Revenue fell 23% to $39.4M, net loss $10M, $179M Pro Farm loss, litigation ongoing.BIOX
Q3 202612 May 2026 - Revenue dropped 20% to $93.3M, but gross margin rose to 40.2% amid global and product mix shifts.BIOX
Q1 202514 Jan 2026 - Over 15 million shares registered for resale, supporting global growth in sustainable agri-biotech.BIOX
Registration Filing16 Dec 2025 - Revenue down 24% to $106.7M, gross margin up to 42%, shift to asset-light, partnership model.BIOX
Q2 20252 Dec 2025 - Gross margin rose to 47% as revenue fell 17% and Adjusted EBITDA jumped 61% year-over-year.BIOX
Q1 202617 Nov 2025 - Revenue fell 28% and net loss reached $55.2M, but operating cash flow rose 27% year-over-year.BIOX
Q4 202511 Sep 2025